Compare iShares MSCI Indonesia ETF (EIDO) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Nuwellis Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.8 (market cap $409.22M), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: iShares MSCI Indonesia ETF is far larger — about 186× Nuwellis Inc's market cap, and iShares MSCI Indonesia ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and Nuwellis Inc for 26 Days on average.
| EIDO | NUWE | |
|---|---|---|
Market Cap | $409.22M | $2.20M |
Volume | 879,527 | 121,544 |
52-Week High | $19.22 | $146.65 |
52-Week Low | $10.80 | $0.68 |
Typical Hold Time | 75 Days | 26 Days |
Sector | — | Health |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.86, down 0.59% with bearish technical signals from moving averages. The ETF faces headwinds as foreign capital rotates away from Asian markets, with recent news highlighting Indonesia's failure to benefit from commodity gains despite attractive valuations. Trading volume declined 21% below average, indicating reduced investor interest.
The outlook remains cautious with technical weakness outweighing valuation appeal. Key risks include heavy financial sector exposure (44%) and limited EPS growth potential. Seasonal patterns historically favor July-August performance, but current market dynamics suggest continued pressure on Indonesian equities amid regional capital outflows.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
